Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

a technology of insulinlike growth factor and conjugate, which is applied in the field of conjugates of insulinlike growth factor and poly(ethylene glycol) can solve the problems of unsuitability for commercial use of many nhs-pegylated proteins and complex regulation of igf-i function, and achieve the effect of superior properties in regard to therapeutic applicability

Inactive Publication Date: 2006-07-13
F HOFFMANN LA ROCHE & CO AG
View PDF7 Cites 33 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0013] It has surprisingly been found that a lysine-PEGylated IGF-I variant (amino-reactive PEGylated IGF-I variant), preferably a 20 kDa to 100 kDa lysine-PEGylated IGF-I variant, and especially preferably a lysine-monoPEGylated IGF-I variant, has superior properties in regard to therapeutic applicability.

Problems solved by technology

The regulation of IGF-I function is quite complex.
However, a major limitation of this approach is that proteins typically contain a considerable amount of lysine residues and therefore the poly(ethylene glycol) groups are attached to the protein in a non-specific manner at all of the free ε-amino groups, resulting in a heterologous product mixture of random PEGylated proteins.
Therefore, many NHS-PEGylated proteins are unsuitable for commercial use because of low specific activity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
  • Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)
  • Conjugates of insulin-like growth factor-1 and poly(ethylene glycol)

Examples

Experimental program
Comparison scheme
Effect test

example 1

Chromatographical Separation of monoPEG-IGF-I Positional Isomers

[0088] IGF-I contains 4 amino groups as potential PEGylation sites and 4 possible monoPEGylated IGF-I (monoPEG-IGF-I) isomers were expected. Further derivates were expected to be oligoPEGylated depending on the reaction conditions. A strong-cation high pressure liquid chromatography method (IEC-HPLC) was developed for the separation of PEG-IGF-I or -Des(1-3)-IGF-I isomers based on their local charge differences. A preparative elution profile of 5 mg PEG-IGF-I is shown in FIG. 1. The result of this method was a separation into 5 major peaks, 3 peaks with baseline separation and 2 with partial separation. The decrease of the baseline absorption towards the end of the chromatogram suggests no additional monoPEGylated IGF-I species eluting at higher retention time. An additional peak appears between peak 3 and 4 resulting from the switch to the modified buffer B with different pH. Analytical IEC-HPLC was used to estimate t...

example 2

SDS-PAGE Analysis of monoPEG-IGF-I Isomers

[0089] SDS-PAGE was performed both under non-reducing and reducing conditions to evaluate potential unwanted cross-linking of different IGF-I molecules through intermolecular disulfide bridges. Both conditions yielded similar results indicating that no significant amount of the protein was abnormally cross-linked (FIG. 2). The SDS-PAGE analysis showed that peak 0 had an apparent molecular weight of >100 kDa whereas the major detected bands were peaks 1-3 at ˜70 kDa; additionally, peak 4 was detected at ˜7 kDa, a size expected for unPEGylated IGF-I (FIG. 2). From this running profile and the retention times obtained in the HPLC we concluded that peak 0 consists most probably of di- and oligoPEG-IGF-I. In contrast, peaks 1-3 were designated as 3 different monoPEG-IGF-I isomers. There was a discrepancy between the expected molecular weight for monoPEG-IGF-I (51.6 kDa) and the apparent size of ˜70 kDa; however, the observed higher apparent mole...

example 3

Analysis of monoPEG-IGF-I Isomers

[0092] Cleavage of rhIGF-I with Asp-N delivered 6 independent peptide fragments that were separated by HPLC between 30 and 45 minutes retention time (FIG. 3A,upper panel). After cleavage of the purified peaks 1 to 3 (FIG. 3A, lower panels), different distributions of the 6 fragments and the occurrence of an additional fragment (fragment 7) was observed eluting at 70 minutes retention time. For peak 1, specifically peptide fragment 4 was diminished with a concomitant increase of fragment 7. For peak 2, we observed a clear decrease in fragment 3 and a slight decrease in fragment 5 and the appearance of a major and a minor PEG fragment (7 and 7′). Similarly, HPLC analysis of peak 3 yielded a clear decrease in fragments 3 and 5 with the concomitant occurrence of fragments 7 and 7′. FIG. 11B shows the peptide sequences of the respective fragments as obtained by Asp-N cleavage of rhlGF-I. Using Edman N-terminal peptide degradation we analyzed the peptide...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

A conjugate consisting of an insulin-like growth factor-1 (IGF-I) variant and one or two poly(ethylene glycol) group(s), characterized in that said IGF-I variant has an amino acid alteration at up to three amino acid positions 27, 37, 65, 68 of the wild-type IGF-I amino acid sequence so that one or two of said amino acids is / are lysine and amino acid 27 is a polar amino acid but not lysine, is conjugated via the primary amino group(s) of said lysine(s) and said poly(ethylene glycol) group(s) have an overall molecular weight of from 20 to 100 kDa is disclosed. This conjugate is useful for the treatment of neurodegenerative disorders like Alzheimer's Disease.

Description

PRIORITY TO RELATED APPLICATIONS [0001] This application claims the benefit of Eropean Application No. 04030415.6, filed Dec. 22, 2004, which is hereby incorporated by reference in its entirety. FIELD OF THE INVENTION [0002] This invention relates to conjugates of insulin-like growth factor-I(IGF-I) with poly(ethylene glycol) (PEG), pharmaceutical compositions containing such conjugates, and methods for the production and methods of use of such conjugates. BACKGROUND OF THE INVENTION [0003] Alzheimer's disease (AD) is an increasingly prevalent form of neurodegeneration that accounts for approximately 50%-60% of the overall cases of dementia among people over 65 years of age. Death of pyramidal neurons and loss of neuronal synapses in brains regions associated with higher mental functions results in the typical symptoms, characterized by gross and progressive impairment of cognitive function. Neuropathologically, the major hallmarks of AD are the presence of two characteristic lesion...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): C07K14/65A61K38/30
CPCC07K14/475A61K47/48215A61K47/60A61P25/28A61P43/00A61K47/50A61K38/30C07K14/62C07K19/00C07K14/65
Inventor AMREIN, BEATFOSER, STEFANLANG, KURTMETZGER, FRIEDRICHREGULA, JOERGSCHAUBMAR, ANDREASHESSE, FRIEDERIKEKUENKELE, KLAUS-PETERLANZENDOERFER, MARTIN
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap